We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current MCRB market cap is 163.57M. The company's latest EPS is USD -0.6661 and P/E is -1.38.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 310k | 64k | 0 | 171k | 0 |
| Operating Income | -47.41M | -44.72M | -39.59M | -31.35M | -21.38M |
| Net Income | -47.85M | -41.25M | -40.13M | -32.87M | 88.78M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 34.51M | 33.22M | 146.66M | 7.13M | 126.33M |
| Operating Income | -71.88M | -88.13M | -64.49M | -246.49M | -107.98M |
| Net Income | -70.28M | -89.13M | -65.58M | -250.16M | -113.72M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 367.7M | 358.6M | 341.26M | 321.73M | 178.74M |
| Total Liabilities | 382.82M | 403.46M | 401M | 408.81M | 154.82M |
| Total Equity | -15.12M | -44.86M | -59.74M | -87.07M | 23.92M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 132.44M | 342.94M | 354.86M | 348.78M | 358.6M |
| Total Liabilities | 180.76M | 168.19M | 223.35M | 338M | 403.46M |
| Total Equity | -48.32M | 174.75M | 131.51M | 10.78M | -44.86M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -69.86M | -117.35M | -35.24M | -75.05M | -109.73M |
| Investing | 11.46M | 10.58M | -62k | 1.24M | 142.38M |
| Financing | 65.28M | 71.71M | 18.41M | 18.76M | -92.11M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -76.52M | -93.61M | 6.69M | -228.82M | -117.35M |
| Investing | -30.52M | -158.89M | 64.09M | 82.43M | 10.58M |
| Financing | 86.23M | 303.42M | 1.18M | 129.6M | 71.71M |
| Market Cap | 163.57M |
| Price to Earnings Ratio | -1.38 |
| Price to Sales Ratio | 1.24 |
| Price to Cash Ratio | 1.23 |
| Price to Book Ratio | -3.5 |
| Dividend Yield | - |
| Shares Outstanding | 170.74M |
| Average Volume (1 week) | 1.93M |
| Average Volume (1 Month) | 2.78M |
| 52 Week Change | -15.22% |
| 52 Week High | 2.05 |
| 52 Week Low | 0.54 |
| Spread (Intraday) | 0.3 (30.65%) |
| Company Name | Seres Therapeutics Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.serestherapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
